| # | Drug | Count |
|---|---|---|
| 0 | ADALIMUMAB | 1302 |
| 1 | BEVACIZUMAB | 954 |
| 2 | PREDNISONE | 753 |
| 3 | METHOTREXATE SODIUM | 459 |
| 4 | DEXAMETHASONE | 435 |
| 5 | DEXAMETHASONE 1.5 MG | 434 |
| 6 | METHOTREXATE | 419 |
| 7 | RITUXIMAB | 393 |
| 8 | INFLIXIMAB | 392 |
| 9 | CYCLOPHOSPHAMIDE | 376 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ENALAPRILAT | 14 | 0.0560 |
| 1 | IBUPROFEN LYSINE | 25 | 0.0443 |
| 2 | BEVACIZUMAB-BVZR | 12 | 0.0174 |
| 3 | BERACTANT | 5 | 0.0137 |
| 4 | ISOFLURANE | 26 | 0.0134 |
| 5 | ZIV-AFLIBERCEPT | 13 | 0.0100 |
| 6 | MIRVETUXIMAB SORAVTANSINE | 15 | 0.0091 |
| 7 | METHYLNALTREXONE BROMIDE | 13 | 0.0087 |
| 8 | EPCORITAMAB-BYSP | 10 | 0.0079 |
| 9 | BEVACIZUMAB | 954 | 0.0077 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 1802 |
| 1 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 1017 |
| 2 | Nonsteroidal Anti-inflammatory Drug [EPC] | 909 |
| 3 | Tumor Necrosis Factor Blocker [EPC] | 803 |
| 4 | Platinum-based Drug [EPC] | 759 |
| 5 | Nucleoside Metabolic Inhibitor [EPC] | 675 |
| 6 | Kinase Inhibitor [EPC] | 562 |
| 7 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 519 |
| 8 | Alkylating Drug [EPC] | 464 |
| 9 | Folate Analog Metabolic Inhibitor [EPC] | 464 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Farnesyltransferase Inhibitor [EPC] | 1 | 0.0130 |
| 1 | Surfactant [EPC] | 7 | 0.0062 |
| 2 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 1017 | 0.0056 |
| 3 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 19 | 0.0052 |
| 4 | CTLA-4-directed Blocking Antibody [EPC] | 230 | 0.0049 |
| 5 | Vascular Endothelial Growth Factor Receptor 2 Antagonist [EPC] | 30 | 0.0048 |
| 6 | Interferon gamma Blocker [EPC] | 1 | 0.0048 |
| 7 | Medium-chain Triglyceride [EPC] | 2 | 0.0038 |
| 8 | Vasoconstrictor [EPC] | 1 | 0.0034 |
| 9 | Serotonin-4 Receptor Agonist [EPC] | 2 | 0.0032 |